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Regulation of replicative functions in the Epstein-Barr virus (EBV) genome is mediated through activation
of a virally encoded transcription factor, Z (BZLF1). We have shown that the Z gene product, which binds to
AP-1 sites as a homodimer and has sequence similarity to c-Fos, can efficiently activate the EBV early
promoter, BMRF1, in certain cell types (i.e., HeLa cells) but not others (i.e., Jurkat cells). Here we
demonstrate that the c-myb proto-oncogene product, which is itself a DNA-binding protein and transcriptional
transactivator, can interact synergistically with Z in activating the BMRF1 promoter in Jurkat cells (a T-cell
line) or Raji cells (an EBV-positive B-cell), whereas the c-myb gene product by itself has little effect. The simian
virus 40 early promoter is also synergistically activated by the Z/c-myb combination. Synergistic transactivation
of the BMRF1 promoter by the Zic-myb combination appears to involve direct binding by the Z protein but not
the c-myb protein. A 30-bp sequence in the BMRF1 promoter which contains a Z binding site (a consensus AP-1
site) is sufficient to transfer high-level lymphoid-specific responsiveness to the Z/c-myb combination to a
heterologous promoter. That the c-myb oncogene product can interact synergistically with an EBV-encoded
member of the leucine zipper protein family suggests c-myb is likely to engage in similar interactions with
cellularly encoded transcription factors.
The discovery that expression of a single Epstein-Barr
virus (EBV) immediate-early (IE) gene product, BZLF1 (Z),
is sufficient to trigger the disruption of viral latency (6, 7, 44,
48) has stimulated a search for the key cellular and viral
elements needed to activate EBV replication. It is now clear
that the Z gene product has significant sequence similarity to
the DNA binding domain of c-Fos (11). The Z protein, like
c-Fos, can bind to the AP-1 site, but in contrast to c-Fos, Z
binds as a homodimer and can also bind to additional
non-AP-1 sites referred to as Z response elements (ZREs) (4,
11, 13, 29, 35, 43, 45, 50, 55).
To date, transcriptional activation of early EBV promot-
ers by Z has been associated with the presence of Z binding
sites in upstream promoter elements. However, we recently
reported that the EBV early BMRF1 promoter, which con-
tains a consensus AP-1 binding site, is transactivated effi-
ciently by Z in certain epithelial cell lines (including HeLa
and HEp-2 cells) but not in several lymphoid cell lines
(including the Jurkat T-cell line and the EBV-negative B-cell
line Louckes) (21). Therefore, it seems likely that cellular
factors, as well as Z itself, are required for efficient transac-
tivation of Z-responsive promoters.
Here we report the first evidence that the cellular c-myb
oncogene can interact synergistically with the Z transactiva-
tor in lymphoid cells. The c-myb gene is the cellular homolog
of the v-myb oncogene and encodes a 75-kDa nuclear protein
(reviewed in reference 38). The v-myb oncogene is carried
by the avian myeloblastosis virus and transforms myeloid,
but not fibroblast, cells (25). Although c-myb is predomi-
nantly expressed in immature hematopoietic cells, it is
expressed at lesser levels in other cell types (1, 37, 42, 51,
52). It has been recently shown that the c-myb protein binds
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specifically to the nucleotide sequence pyAACG/TG and can
activate promoters carrying multiple copies of this sequence
(2, 14, 22, 24, 28, 41, 59). However, there is some evidence
to suggest that transcriptional activation by c-myb may
require interaction with other transcriptional activators.
Ibanez and Lipsick (24) have reported that v-Myb binding is
required, but apparently not sufficient, for activation of
target promoters containing several copies of the consensus
Myb binding site. Furthermore, v-myb-induced transactiva-
tion of certain promoters has been reported to occur through
a nonbinding mechanism (27).
In addition to the c-myb protein, cDNA clones of two
closely related proteins, A-Myb and B-Myb, have been
isolated (42). The A-myb and B-myb proteins, which are
expressed at high level in a wider variety of tissues than is
c-Myb, have DNA binding domains very similar to that of
c-Myb (42). It has recently been confirmed that the B-myb
protein, like c-Myb, can bind to the consensus c-myb binding
site and function as a transcriptional activator (39). In
addition, there are several different splicing variants of
c-Myb, some of which affect the regulatory sequences of the
protein (47, 57, 58). Transcriptional regulation of promoters
containing Myb binding sites is therefore likely to be cell
type specific, depending on the relative proportions of the
different myb proteins in each cell type.
Here we show that the EBV early BMRF1 promoter can
be activated synergistically by the combination of Z and
c-myb in Jurkat cells (a T-cell line) or Raji cells (an EBV-
positive B-cell line), whereas Z by itself efficiently activates
the BMRF1 promoter in two different epithelial cell lines.
We map the region of the BMRF1 promoter required for
maximal response to the Zlc-myb combination to a 30-bp
stretch containing a consensus AP-1 site and show that this
sequence is sufficient to confer responsiveness to the Z/c-
myb combination to a heterologous promoter. The simian
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virus 40 (SV40) early promoter, which contains an AP-1
binding site (33), is also synergistically activated by the
Zlc-myb combination. The demonstration that c-myb can
interact synergistically with an EBV-encoded transactivator
to activate two different promoters suggests that c-myb is
likely to interact in a similar fashion with as yet unidentified
cellular transcription factors.
MATERIALS AND METHODS
Cell lines. The cell lines used were the EBV-negative
T-cell line Jurkat, the EBV-positive Burkitt's lymphoma line
Raji, the cervical epithelial cell line HeLa, and an EBV-
positive epithelial cell line, NPC-KT (49), made by fusing an
adenoidal carcinoma line with a nasopharyngeal carcinoma
line. Lymphoid lines were maintained in RPMI 1640 medium
supplemented with 10% fetal calf serum. Epithelial cells
were maintained in Dulbecco modified Eagle medium H
supplemented with 10% fetal calf serum.
DNA transfections. Plasmid DNA was purified through two
sequential cesium chloride gradients. Transfection of DNA
into both lymphoid and epithelial cell lines was accom-
plished by using electroporation (54). For each condition,
107 cells were shocked at 1,500 V, using the Zapper electro-
poration unit (Medical Electronics Shop, University of Wis-
consin). Epithelial cells were harvested and resuspended in
RPMI 1640 medium for electroporation.
EA-CAT plasmids. The EA-CAT constructs used in this
study (some of which have been previously described [21])
are shown in Fig. 1. The parent construct, pEA-CAT,
contains the promoter of the BMRF1 gene from sequences
-331 to +1 (relative to the RNA start site) linked to the
chloramphenicol acetyltransferase (CAT) gene. 5' deletions
of EA-CAT (Fig. 1A) were made by cutting with various
restriction enzymes, blunt ending, and religating. These
mutants are named to reflect the promoter sequences (rela-
tive to the mRNA start site of BMRF1) contained within
each construct. Plasmid pEA-BS-CAT (used for site-di-
rected mutagenesis) contains the BMRF1 promoter se-
quences (-331 to +1) linked to the CAT gene in the
Stratagene m13 Bluescript SK+ phagemid vector (Fig. 1B).
Site-directed mutants that remove the AP-1 site, another Z
binding site (ZRE), or the potential c-Myb binding site were
constructed from the pEA-BS-CAT plasmid as shown in Fig.
lB.
The ElB-EAD-CAT plasmid was made by ligating three
copies of the 30-bp BMRF1 promoter sequence from 79801
to 79830 (-69 to -39 relative to the mRNA start site)
directly upstream of the adenovirus E1B TATA box in the
ElB-CAT construct (36) (a gift from Katherine Martin and
Michael Green) between the XbaI and Pst restriction sites.
EBV Z transactivator plasmids. Two different Z expression
vectors were used in these experiments. Most experiments
were performed with the pEBV-ZIE construct, which as
previously described (21) contains the EBV genomic frag-
ment encoding the Z gene product inserted into the pHD1013
vector under the control of the cytomegalovirus (CMV) IE
promoter. In experiments using pEBV-ZIE, equal amounts
of the pHD1013 vector (containing the CMV IE promoter
but no Z gene) versus the EBV-ZIE plasmid were trans-
fected in parallel to control for promoter competition effects.
Deletional analysis of the Z protein was performed by
using a series of deletions derived from the parental vector,
pKSV41. As previously described (16), the pKSV41 con-
struct is a pUC18-based plasmid which contains the Z cDNA




































FIG. 1. (A) Construction of 5' deletions of pEA-CAT. The
parent pEA-CAT construct contains the EBV BamHI-RsaI frag-
ment (EBV nucleotides 79537 to 79870) linked to CAT. A series of
5' deletion mutants was constructed by cutting at the indicated
restriction endonuclease site, blunt ending with T4 polymerase or
Klenow enzyme, and religating. The sites of the TATA box and
potential AP-1 binding site are shown. (B) Construction of site-
directed mutations. The parent construct, pEA-BS-CAT, contains
the EBV BamHI-RsaI fragment linked to CAT in a phagemid
vector. The AP-1 site, an additional upstream Z binding site (ZRE),
and the potential c-Myb binding site were abolished by using the
Kunkel method (30) of site-directed mutagenesis as shown.
As shown in Fig. 2A, in-frame deletional mutants of Z were
constructed by cutting at convenient restriction enzyme
locations and religating. The mutants are named to reflect
the location of the Z amino acids that were deleted. The
stability and cellular localization of these mutants was tested
by transfection of the mutated versus wild-type pKSV41
plasmids into COS-7 cells, separation of the nuclear and
cytoplasmic fractions, sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis, and immunoblotting. This analy-
sis (which is presented in detail elsewhere [16]) indicated
that two of the mutant proteins, produced from plasmids
ZA42-191 and ZA140-227, were unstable, while the other
mutant proteins were all as stable as the wild-type protein.
Of the mutant proteins that were shown to be stable, all
except ZA200-227 were shown to have nuclear localization.
Since all of the mutations shown in Fig. 2A which involved
the DNA binding domain of the Z protein either were found
to be unstable or did not localize within the nucleus, we also
tested a mutant containing a site-directed mutation within
the DNA binding domain of Z (plasmid pZ311; Fig. 2B). The
Z311 mutant produces Z protein which is stable and localizes
to the nucleus, although the protein has completely lost
DNA binding activity (16).
c-myb transactivator plasmids. The parental c-myb expres-
sion vector, pRmb3SVneo, which has been previously de-
scribed (10), contains a mouse c-myb cDNA under the
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FIG. 2. (A) Construction of the EBV Z transactivator plasmids.
The parent plasmid, pKSV41, contains the Z cDNA driven by the
SV40 early promoter and enhancer in a pUC18-based plasmid as
previously described (16). In-frame deletion mutants of pKSV41
were created by cutting with convenient restriction enzymes, blunt
ending, and religating as shown. The mutants are named to reflect
the position of the amino acids removed from the Z protein. The
positions of the previously mapped transactivation domain, DNA
binding domain, and dimerization domain within the Z protein are
indicated. Nuclear (Nu) versus cytoplasmic (Cy) localization is
indicated. (B) Construction of plasmid Z311. The Z311 plasmid
contains a site-directed mutation in the DNA binding domain as
shown. The resultant protein cannot bind DNA but is stable and
localizes in the nucleus.
control of the Rous sarcoma virus long terminal repeat in
addition to the neomycin resistance gene driven by the SV40
promoter. The vector pJTmyb-fs, which is identical to
pRmb3SVneo except for a frameshift mutation within the
c-myb coding sequence (10) (a gift from Jenny Ting), was
used to control for vector effects in experiments using the
pRmb3SVneo plasmid. MybA2R was constructed by remov-
ing the first and second 51- to 52-amino-acid repeat elements
(which contain the DNA binding domain of c-Myb) by the
polymerase chain reaction technique and recloning the re-
mainder of the c-myb protein into the pHD1013 vector under
the control of the CMV IE promoter. Potential CMV IE
promoter competition effects were controlled for by includ-
ing a transfection condition with the pHD1013 vector alone
(without c-myb) as a control in all experiments using this
construct.
CAT assays. Cells were transfected with 10 jig of plasmid
DNA, using the electroporation method. Forty-eight hours
after transfection, a cell extract was prepared and incubated
at 37°C with 14C-labelled chloramphenicol in the presence of
acetyl coenzyme A as described previously (17). The percent
acetylation of chloramphenicol was quantitated by thin-layer
chromatography followed by autoradiography and scintilla-
tion counting. Some of the CAT assays shown in Fig. 3 and
8 are off-scale and thus represent potential underestimations
of the actual Z/c-myb synergy. For the calculations shown in
the tables and Fig. 9, CAT assays were repeated if results
were not in the linear range (less than 80% chloramphenicol
acetylation), using smaller amounts of extract.
Western immunoblots. To quantitate the level of Z protein
expression in transfected cells, 107 Jurkat cells were trans-
fected as described above. The cells were harvested after 48
h (a portion was used for the CAT assay), washed with
phosphate-buffered saline (PBS) twice, resuspended in 0.25
M Tris (pH 8.0), lysed by freeze-thaw and sonication, and
cleared by centrifugation. The soluble proteins were sepa-
rated by electrophoresis through a 12.5% polyacrylamide gel
and transferred electrophoretically to nitrocellulose. The
preblocked nitrocellulose filter was incubated for 1 h at 37°C
with a 1:100 dilution of pooled sera from patients with
nasopharyngeal carcinoma (a gift from Pierre Buisson),
followed by human anti-immunoglobulin G-peroxidase con-
jugate. The coloring agent was developed by incubation in
3,3'-diaminobenzidine and hydrogen peroxide.
RNA analysis. CAT mRNA was quantitated using Si
nuclease protection (12). Cytoplasmic RNA was prepared 24
h after transfection as previously described (15). A 20-bp
oligonucleotide primer homologous to the CAT gene in the
region 240 to 254 bp downstream of the ATG codon was
synthesized and hybridized to single-stranded DNA pro-
duced from the EA-PBS-CAT phagemid construct. A com-
plementary single-stranded uniformly labelled DNA probe
was subsequently synthesized by extending the oligonucle-
otide with Klenow enzyme in the presence of 32P-labelled
dCTP, cutting the DNA with XbaI (located directly up-
stream of the 332-bp BMRF1 promoter element), and isolat-
ing the resultant approximately 600-bp single-stranded probe
on a denaturing acrylamide gel. The probe was then hybrid-
ized overnight with cytoplasmic RNA in a solution contain-
ing 80% formamide, 40 mM PIPES [piperazine-N,N'-bis(2-
ethanesulfonic acid)], 400 mM NaCI, and 1 mM EDTA and
digested with S1 nuclease, and the protected fragments were
electrophoresed on a 6% acrylamide-7 M urea gel.
In vitro site-directed mutagenesis. Mutants were made by
using the Bio-Rad Muta-Gene phagemid in vitro mutagenesis
kit according to a method described by Kunkel (30). Mutants
were made by using a synthetic oligonucleotide complemen-
tary to the region to be altered except for a limited internal
mismatch. For screening possible mutants, synthetic oligo-
nucleotides were designed to create new restriction sites.
The AP-1 mutation has been previously described (21).
Z binding studies. The Z protein was in vitro transcribed
and translated by using wheat germ lysate from the SP64
vector containing Z cDNA (44) (a gift from Paul Farrell). A
32P-end-labelled probe containing BMRF1 promoter se-
quences from -79 to +128 was incubated with 5 ,ul of in
vitro-translated Z protein for 30 min at room temperature.
Binding reactions were performed in buffer containing 100
mM KCI, 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-
2-ethanesulfonic acid; pH 7.3), 10% glycerol, 0.2 mM
EDTA, 4 mM dithiothreitol, 5 mM phenylmethylsulfonyl
fluoride, and 2 ,ug of poly(dI-dC) - poly(dI-dC). For methyl-
ation protection studies, dimethylsulfate (1 ,ul) was added to
the binding reaction immediately prior to loading onto a 5%
polyacrylamide-0.5% Tris-borate-EDTA gel. Two bands
representing the bound probe and one band representing the
free probe were cut from the gel and transferred to DEAE
membrane paper. The membrane was incubated with 1 M
piperidine at 90°C for 30 min and then rinsed twice with
sterile water. The probe fragments were then eluted by
incubating the membrane with 1 M NaCl-0.1 mM EDTA-20
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bound and free probes were then analyzed on a 6% poly-
acrylamide-7 M urea gel.
Myb binding studies. Potential myb protein binding to the
BMRF1 promoter was studied by using a bacterial fusion
v-myb protein (14) (a gift from J. Lipsick) which has been
previously described (14). v-Myb binding to the BMRF1
promoter was analyzed by using a synthetic double-stranded
oligonucleotide sequence (oligonucleotide EAD) containing
the BMRF1 promoter sequences from -50 to -83 relative to
the mRNA start site flanked by EcoRI and SalI restriction
sites (ATGTCGACGAATTCGCTGGTGGTAGATGACCT
TTGAGTCAGGGTGGCTGTCGACACA). Oligonucleotide
sequences containing mutations in the AP-1 site (EAD AP-1;
ATGTCGACGAATTCGCTGGTGGTAGATGACCTTTC
AGCTGGGGTGGCTGTCGACACA) or the potential c-myb
site (EAD MYB; ATGTCGACGAATTCGCTGGTGGTAG
ATTCTAGATGAGTCAGGGTGGCTGTCGACACA)
were also analyzed. An oligonucleotide containing four
copies of a consensus c-Myb binding site (CAGTTA) was
also constructed (MYB; CCGAATTCCAGTTAATAGCAG
TTAATAGCAGTTAATAGCAGTTAATl-T) to use as a pos-
itive control for Myb binding. Gel mobility shift assays were
performed by incubating the renatured, double-stranded
synthetic oligonucleotides (after end labelling with 32P by
Klenow reaction) with protein extracts from the bacteria
producing v-myb protein (T7MYB) or protein extracts from
bacteria containing the negative control vector (MYBLESS)
in a reaction buffer containing 10 mM Tris-HCI (pH 7.5), 50
mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 5% glycerol,
And 80 jig of poly(dI-dC) - (poly(dI-dC) per ml for 30 min at
4°C. Free and bound complexes were then resolved by
electrophoresis in a polyacrylamide gel in 0.5 x Tris-borate-
EDTA buffer at 40 V cm-' for 30 min at 4°C and subjected
to autoradiography. The effect of anti-myb antibody on
bound complexes was determined by comparing the results
of mixing 1 p1 of preimmune rabbit serum versus 1 RI of
rabbit polyclonal anti-try-myb 2 serum (3) (a gift from J.
Lipsick) into the reaction mixture 30 min before adding the
labelled probe.
RESULTS
The EBV BMRF1 promoter and the SV40 early promoter
are synergistically activated by the combination of Z and
c-myb in lymphoid cells. We first examined the ability of the
c-myb oncogene to complement the Z gene product in
transient cotransfection assays in which the BMRF1 early
EBV promoter was linked to the heterologous CAT gene.
Figure 3 shows the results of representative CAT assays. In
the Jurkat T-cell line (Fig. 3A), the activity of the BMRF1
promoter (linked to CAT) was only slightly increased by
cotransfection with Z alone (one- to eightfold increase in
multiple experiments) or by cotransfection with c-myb alone
(one- to sevenfold increase). Most striking was the effect of
Z and c-myb together in this cell type, producing increases in
EA-CAT activity from 25- to 150-fold in different experi-
ments. In the EBV-positive B-cell line Raji (Fig. 3B), the
effect of Z alone is more efficient, since Z activates the
expression of another EBV-encoded transactivator, BRLF1,
and we have previously shown that Z and BRLF1 interact
synergistically to activate the BMRF1 promoter in lymphoid
cells (21). Nevertheless, the addition of c-myb to Z in Raji
cells consistently results in approximately fourfold-higher
levels of BMRF1 promoter activation than seen with Z
alone, even though the c-myb transactivator by itself has
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FIG. 3. Evidence that the EBV Z transactivator/c-myb combina-
tion synergistically activates the EBV BMRF1 and SV40 early
promoters. The BMRF1 promoter-CAT construct (EAD-CAT) was
transfected into the Jurkat T-cell line (A), the EBV-positive Bur-
kitt's lymphoma cell line Raji (B), HeLa cells (C), or the EBV-
positive epithelial cell line NPC-KT (D). The EAD-CAT plasmid
was cotransfected with either vector control DNA, the Z transacti-
vator alone, the c-myb transactivator alone, or the Z and c-myb
transactivators together. In Jurkat and Raji cells, the combination of
Z and c-myb is synergistic, whereas in HeLa and NPC-KT cells, Z
alone is as effective as Z and c-myb together. The SV40 early
promoter (pAlOCAT) (31) is also synergistically activated in Jurkat
cells by the combination of Z and c-myb (E).
type. However, the combination of Z and c-myb was no
more effective than Z alone in two different epithelial lines,
the EBV-negative HeLa cell line (Fig. 3C) and the EBV-
positive NPC-KT cell line (Fig. 3D). In these cell lines, Z by
itself efficiently transactivates the BMRF1 promoter.
The SV40 early promoter (pAlOCAT construct) (31),
which contains an AP-1 binding site, was also synergistically
activated by the combination of Z and c-myb in Jurkat cells
(Fig. 3E). However, c-myb did not affect the activity of the
EBV BMLF1 promoter (with or without Z) (data not
shown), although this promoter contains an AP-1 site which
has previously been shown to bind the Z protein (11).
BMRF1-driven CAT RNA is increased by the ZIc-myb
combination. In previous studies, we have mapped the RNA
start site of the BMRF1 promoter to EBV sequence 79869
(approximately 25 bp downstream of a potential TATA box
element) and shown that the RNA start site is not altered in
the presence of the Z transactivator (21). In this study, we
used Si nuclease analysis to examine the effect of the
ZIc-myb combination on the steady-state level of EA-CAT
RNA. In the experiment shown in Fig. 4, 5 ,ug of the
EA-CAT construct was cotransfected with 5 ,ug of either
vector DNA alone (pHD1013), the c-myb construct alone,
the EBV-ZIE construct (a vector which contains the Z gene
product in plasmid pHD1013 driven by the CMV IE pro-
moter [21]) alone, or the combination of c-myb and Z.
Cytoplasmic RNA was harvested 24 h after transfection,
hybridized to a uniformly 32P-labelled single-stranded DNA
probe homologous to the EA-CAT gene sequences extend-
ing from 254 bp downstream of the CAT ATG codon to 331
bp upstream of the presumed RNA start site, and digested
E
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FIG. 4. Effect of the Zic-myb transactivator combination on
steady-state CAT mRNA level. The BMRF1 promoter-CAT con-
struct (EAD-CAT) was transfected into Jurkat cells with either
control vector DNA, the Z transactivator alone, the c-myb transac-
tivator alone, or the combination of both transactivators. Cytoplas-
mic RNA was harvested 24 h after transfection, hybridized with a
complementary 32P-labelled single-stranded DNA probe extending
from 331 bp upstream of the expected RNA start site to 254 bp
downstream of the CAT ATG codon, and digested with Si nuclease.
The combination of the Z and c-myb transactivators significantly
increased the level of EAD-CAT mRNA. nt, nucleotides.
with Si nuclease. In cells transfected with the Zlc-myb
combination, an Si-protected fragment of the expected size
(approximately 260 bp) is observed; moreover, the level of
EA-CAT mRNA is clearly increased.
Localization of the BMRF1 promoter regions required for
response to the Zic-myb combination. To define the region(s)
of the BMRF1 promoter that is required for maximal respon-
siveness to the Zlc-myb transactivator combination, we
constructed a series of 5' deletions of the BMRF1 promoter
(linked to CAT) as previously described (21) and tested the
ability of each construct to respond to Z alone or to the
combination of Z plus c-myb in lymphoid cells (Table 1).
In this set of experiments, the parent construct, which
contains BMRF1 promoter sequences from -331 to +1
TABLE 1. Effects of the Z transactivator alone and of the
ZIc-myb combination on pEA-CAT deletion
plasmids in Jurkat cells
Fold increase in CAT activity"
Plasmid Z transactivator Zlc-myb
Avg Range Avg Range
pEA-CAT(-331/+1) 2.3 2.1-2.4 92.8 47.6-137.9
pEA-CAT(-265/+1) 11.9 4.0-19.7 152.5 152.1-152.8
pEA-CAT(-214/+29) 3.4 2.5-4.2 37.3 14.5-50.0
pEA-CAT(-79/+ 1) 1.5 0.5-2.4 32.3 30.2-34.3
pEA-CAT(-62/+29) 0.7 0.7-0.7 2.2 1.7-2.6
a Values represent the average fold increase in CAT activity when each
CAT plasmid was cotransfected with the Z transactivator alone (pEIBV-ZIE)
or with the combination of Z and c-myb. Ranges are those seen in two
experiments.
relative to the RNA start site, was transactivated an average
of 93-fold by the combination of Z and c-myb, versus only
2.3-fold by Z alone in the same set of experiments. The effect
of the Z transactivator alone (as was observed previously
[21]) could be significantly increased by deleting the se-
quences between -331 and -265, although even with this
construct the effect of Z and c-myb together was still much
greater than that of Z alone (152-fold transactivation versus
12-fold). A significant loss in the response of the promoter to
the Zic-myb combination occurred when the sequences
between -265 and -214 were deleted, although a substantial
transactivation effect still remained (37-fold transactivation).
The most precipitous drop in transactivation with the Z/c-
myb combination occurred when the sequences between
-79 and -62 were deleted, with transactivation decreasing
from 32-fold to only 2-fold as these sequences were re-
moved. Thus, the sequences between -62 and -79 appear
to be most important for response of the EAD promoter to
the Zlc-myb combination.
The Z protein binds to the AP-1 site in the BMRF1
promoter. Although the BMRF1 promoter contains a con-
sensus AP-1 binding site, the binding of Z protein to this
promoter has not been previously studied. We used in
vitro-transcribed and -translated Z protein to study Z binding
to the BMRF1 promoter. In gel retardation assays (Fig. 5A),
in vitro-translated Z protein produced retarded bands when
incubated with a 32P-labelled probe encompassing the
BMRF1 promoter sequences from -79 to +128 (relative to
the mRNA start site). Z binding to this probe was specifically
competed for by cold competitor oligonucleotide DNA
(EAD) encompassing the BMRF1 promoter sequences from
-50 to -83 (which contains the AP-1 site) but not by
competitor DNA (AAP-1) in which the AP-1 site in the
BMRF1 sequence had been mutated. Competitor DNA
(AMYB) in which the potential c-Myb binding site had been
mutated competed for Z binding with the same affinity as did
the wild-type sequence. Methylation protection studies of
the bound DNA fragments confirmed that the Z protein, as
expected, binds to the AP-1 site in the BMRF1 promoter
(Fig. SB). Z also binds to one other site in the BMRF1
promoter (a ZRE site) located at position -106 relative to
the mRNA start site (43a).
Roles of the BMRF1 promoter AP-1 site and a potential
c-Myb binding site in the ZIc-myb transactivation response.
The 5' deletional analysis of the BMRF1 promoter suggested
that sequences located between -62 and -79 were required
for maximum response to the Zlc-myb combination. Exam-
ination of the BMRF1 promoter sequence from -62 to -79
(Fig. 1B) reveals that it contains a consensus AP-1 site,
TGAGTCA. In addition, overlapping the AP-1 site is the
sequence CCTTTG, which is a 1-bp mismatch from the
consensus c-Myb binding sequence (C/T)AAC(G/T)G, or
C(A/C)GTT(AIG) when read on the opposite strand 5' to 3'.
Further upstream (-106 relative the mRNA start site) is
another Z binding site (43a) homologous to previously re-
ported ZREs (4, 11, 13, 29, 35, 43, 45, 50, 55).
To determine whether the AP-1 site, the ZRE, or the
potential c-Myb binding site contributes to transactivation of
the BMRF1 promoter by the ZIc-myb combination, we made
site-directed mutations which specifically abolished either
the AP-1 site alone, the AP-1 site and the ZRE simulta-
neously, or the potential c-Myb binding site. We then tested
these mutated promoter constructs for the ability to respond
to Z alone, c-myb alone, or the combination of Z and c-myb
(Table 2).
In this set of experiments, the average fold increase in
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FIG. 5. Binding of the Z protein to the AP-1 site in the BMRF1
promoter. (A) In vitro-transcribed and -translated Z protein was
incubated with a 32P-labelled probe containing the BMRF1 promoter
sequences from -79 to +126 (relative to the mRNA start site) at
23'C for 30 min, and then the products were resolved by gel
electrophoresis and autoradiography. The in vitro-translated Z
protein produced retarded complexes with the BMRF1 promoter
probe that were not seen with the untranslated wheat germ extract
alone (last lane). Competition studies showed that cold competitor
DNA (at 20- and 100-fold molar excess) containing the BMRF1
promoter sequences from -50 to -83 (oligonucleotide EAD) spe-
cifically competed for Z binding. Cold competitor DNA containing
the same BMRF1 sequences but with the AP-1 site abolished
(oligonucleotide AAP-1) did not compete. Competitor DNA which
abolished the potential c-Myb binding site (oligonucleotide AMYB)
competed for Z binding with the same efficiency as did the wild-type
sequence. (B) A 32P-end-labelled probe containing the BMRF1
promoter sequences from -79 to +126 was incubated with in
vitro-translated Z protein and then treated with dimethylsulfate
immediately prior to gel electrophoresis. Two different retarded gel
complexes (lanes 2 and 3, with lane 3 having the most retarded
complex) and the free probe (lane 1) were removed separately, cut
with piperidine, and then analyzed on a 6% polyacrylamide-urea
gel. The position of the AP-1 binding site is as shown. Binding by Z
to the BMRF1 probe appears to protect the BMRF1 probe from
methylation.
EA-CAT activity induced by Z alone in Jurkat cells was 3.8,
the average fold increase induced by c-myb alone was 2.5,
and the average fold increase induced by both transactiva-
tors together was 32.3. When the AP-1 site was abolished by
site-directed mutation, the effect of Z alone decreased sig-
nificantly (down to 0.9), as did the effect of Z and c-myb
together (down from 32.3 to 8.5). The residual 8.5-fold effect
of the Zlc-myb combination on this mutant was essentially
lost when the upstream ZRE was also destroyed (down to
2.4-fold effect). Therefore, it appears that at least one Z
TABLE 2. Effects of the Z transactivator, the c-myb
transactivator, and the Zlc-myb combination on
pEA-BS-CAT site-directed mutants in Jurkat cells
Fold increase in CAT activity'
Plasmid Z alone c-myb alone Z/C-myb
Avg Range Avg Range Avg Range
pEA-BS-CAT 3.8 1.2-5.8 2.5 0.9-3.5 32.3 22.6-39.8
pEAAAP-1-CAT 0.9 0.6-1.2 1.7 1.1-2.2 8.5 4.5-15.9
pEAAAP-1/106 0.3 0.1-0.7 1.7 0.4-2.8 2.4 1.8-6.0
pEAAMYB-CAT 12.9 6.9-23.5 3.2 1.7-4.6 40.2 22.8-61.1
' Values represent the average fold increase in CAT activity when each
CAT plasmid was cotransfected with Either Z alone, c-myb alone, or the
combination of both transactivators. Ranges are those seen in three experi-
ments.
binding site is required for the synergistic Z/c-myb transac-
tivation effect.
When the potential c-Myb binding site was abolished by
site-directed mutation, the effect of both transactivators
together was not diminished, nor was the effect of c-myb
alone. Therefore, it seems unlikely that the Zlc-myb synergy
is mediated through binding of c-Myb to this site. In fact, it
would be somewhat surprising if c-Myb were to bind to this
site, since the substitution of C to A in the fourth position of
the consensus Myb binding site (PyAACG/TG) has been
previously shown to inhibit binding by v-Myb (23). How-
ever, the effect of Z alone in Jurkat cells was unexpectedly
somewhat increased (from 3.8- to 12.9-fold).
v-myb protein does not bind to the BMRF1 promoter.
Although site-directed mutagenesis of the CCTTTG se-
quence suggested that this sequence itself is not required for
Zlc-myb activation of the BMRF1 promoter, c-Myb could
potentially bind elsewhere in the promoter, using a novel
binding site. Since the binding affinities of the c-myb and
v-myb proteins are thought to be essentially identical, we
used a bacterial vector expresging a v-myb fusion protein (a
gift from J. Lipsick), T7MYB (14), to study potential myb
protein binding to the BMRF1 promoter. Using this fusion
protein, we routinely observed strong binding to a control
probe corltaining four copies of the consensus Myb binding
site (Fig. 6). As expected, biidirld by v-Myb was inhibited by
a 20-fold molar excess of competitor DNA containing the
consensus c-Myb binding site. HIowever, two different oli-
gonucleotides containing the potential Myb binding site in
the BMRF1 promoter (oligonucleotides EAD and EAD
AP-1) were unable to compete for v-Myb binding, even at a
300-fold molar excess. Likewise,e a 32P-labelled probe con-
taining the potential Myb binding site in the BMRF1 pro-
moter did not bind the v-myb protein (data not shown).
Therefore, it appears unlikely that c-Myb can bind to the
BMRF1 promoter independently. However, since c-Myb
binding may be stabilized by cellular factors, we cannot
totally exclude the possibility that c-Myb may bind to the
BMRF1 promoter in vivo.
A 30-bp BMRF1 promoter sequence is sufficient to transfer
Zlc-myb responsiveness to a heterologous promoter. To deter-
mine whether the BMRF1 promoter sequences containing
the AP-1 binding site are sufficient to confer Zic-myb respon-
siveness to a heterologous promoter, we inserted three
copies of the 30-bp BMRF1 sequence (ACCTTTGAGTC
AGGGTGGCTACTTGCTCAG) located from -39 to -69
(relative to the mRNA start site) upstream of the adenovirus
E1B TATA box in the ElB-CAT plasmid (a gift from
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FIG. 6. Evidence that v-myb protein expressed in Escherichia
coli does not bind to the BMRF1 promoter. Bacterial v-myb was
expressed at high level in isopropyl-3-D-thiogalactopyranoside
(IPTG)-induced E. coli bearing the pT7MYB vector (a gift from J.
Lipsick) as previously described (14). Equal amounts of protein
from bacterial extracts containing the pT7MYB vector or from the
negative control vector pT7MYBLESS were incubated at 4°C for 30
min with a 32P-labelled oligonucleotide probe containing four copies
of the consensus Myb binding site. The products were then resolved
by nondenaturing gel electrophoresis and autoradiography. v-mvb
protein was shown to bind to the consensus c-Myb binding site as
expected. Competition studies confirmed that a 20-fold molar excess
of cold oligonucleotide containing the consensus c-Myb binding site
(oligonucleotide MYB) competed for binding to the labelled myb
probe, whereas a 300-fold excess of two different oligonucleotides
(EAD and AP-1) containing the potential c-Myb binding site in the
BMRF1 promoter did not compete. The myb-specific antibody (3),
as expected, decreased v-Myb binding to the MYB probe, whereas
preimmune serum had no effect. A labelled probe containing the
potential c-Myb binding site in the BMRF1 promoter did not bind
the v-myb protein (data not shown).
Michael Green and Katherine Martin). As shown in Fig. 7,
the -39 to -69 region of the BMRF1 promoter (which
contains the AP-1 binding site but not the upstream ZRE
binding site) is sufficient to transfer high-level responsive-
ness to the ZIc-myb combination. Furthermore, the trans-
ferred responsiveness to Zlc-myb continues to be lymphoid
specific, in that it is observed in Jurkat cells but not in HeLa
cells.
c-myb does not increase the level of transfected Z protein.
One mechanism by which the c-myb and Z transactivator
plasmids might interact synergistically would be through the
ability of transfected c-myb to increase the level of trans-
fected Z protein. To exclude this possibility, we performed
an experiment in Jurkat cells in which the level of Z
expression in the presence and absence of c-myb was
determined in a portion of the cell extract, and the level of
BMRF1-CAT activity was simultaneously determined in the
same protein extracts. As expected, the level of BMRF1-
driven CAT activity is much higher in the presence of Z and
c-myb together than with Z alone (Fig. 8B). Furthermore,
the level of transfected Z (determined by immunoblotting) is
similar in each condition (Fig. 8A), excluding the possibility
that the increased CAT activity in the ZIc-myb condition is
due to increased Z expression or differences in transfection
efficiency. In addition, we found that the level of transfected
Z tended to be consistently higher in Jurkat cells than in
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FIG. 7. Evidence that lymphoid-specific responsiveness to the
Z/c-myb combination can be transferred to a heterologous promoter
by a 30-bp BMRF1 promoter sequence. Three copies of the 30-bp
BMRF1 promoter sequence from -39 to -69 relative to the mRNA
start site were inserted into the ElB-CAT construct upstream of the
adenovirus E1B TATA box. In Jurkat cells (A), the parent con-
struct, ElB-CAT, is not significantly activated by cotransfection
with Z alone, c-myb alone, or the combination of the two transac-
tivators. In contrast, the combination of Z and c-myb together
synergistically activates the ElB-EAD-CAT construct containing
three copies of the BMRF1 AP-1 site in Jurkat cells (B). However,
the E1B-EAD-CAT plasmid is not significantly activated by the
combination of Z and c-myb in HeLa cells (C).
HeLa cells (data not shown), further ruling out the possibil-
ity that inefficient Z transactivation in Jurkat cells is simply
due to insufficient expression of the Z transactivator in this
cell type.
Defining domains in the Z protein required for synergy with
c-myb. To determine which portions of the Z protein are
required for transactivation of the EA-CAT plasmid in
cooperation with c-myb, we tested a series of in-frame
deletion mutants of the Z protein for the ability to activate
EA-CAT activity with and without the c-myb protein (Fig.
9). The parental construct used in these experiments con-
tains the BZLF1 cDNA driven by the SV40 promoter (16). A
number of in-frame deletions were constructed (Fig. 2A)
which delete portions of the protein important for transacti-
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FIG. 8. Evidence that c-myb does not increase the level of
transfected Z protein. To exclude the possibility that c-myb in-
creases the level of transfected Z protein, immunoblotting was
performed (using sera from patients with nasopharyngeal carci-
noma) in Jurkat cells on a portion of the protein extract simulta-
neously harvested for CAT activity. The level of Z protein is similar
when Z is transfected alone or with c-myb (A), whereas the
EAD-CAT activity is much higher in the cells transfected with both
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FIG. 9. Effects of Z and c-myb protein deletions on synergistic activation of the BMRF1 promoter. The EAD-CAT construct was
cotransfected into Jurkat cells with either the pHD1013 vector alone, the wild-type Z transactivator (WT Z) or the various Z deletion mutants
(Fig. 2), the wild-type c-myb protein (WT MYB), or a mutant c-myb protein in which the first two 51- to 52-amino-acid repeats had been
deleted. The fold activation of EAD-CAT activity produced by the various combination of wild-type and mutant proteins is shown. (A)
EAD-CAT plasmid cotransfected with wild-type Z (either alone or in combination with wild-type c-myb) versus various Z deletion mutants
(an average of four separate experiments). (B) EAD-CAT plasmid cotransfected with wild-type Z (either alone or in combination with
wild-type c-myb) versus the Z311 site-directed mutant (an average value from three experiments). (C) EAD-CAT plasmid cotransfected with
mutant c-myb with and without wild-type Z (an average from two experiments).
cellular localization of each mutant protein is shown in Fig.
2A.
In the first set of experiments (Fig. 9A), the average effect
of wild-type Z alone was 7-fold, the average effect of
wild-type c-myb alone was 6-fold, and the average effect of
wild-type Z and wild-type c-myb together was 104-fold.
Deletions which abolished the ability of Z to bind in vitro
(either through deletion of the DNA binding domain or
through deletion of the dimerization domain) all essentially
abolished the ability of Z to interact synergistically with
c-myb in activating EA-CAT expression. However, all of the
deletions shown in Fig. 9A which affected DNA binding also
were subsequently determined to affect protein stability or
nuclear localization. Therefore, we confirmed the impor-
tance of the Z DNA binding function for synergy with c-myb
by testing the Z311 plasmid, which contains a site-directed
mutation in Z which abolishes DNA binding capacity but
does not affect protein stability or nuclear localization (Fig.
9B). The Z311 mutant did not interact synergistically with
c-myb, confirming the importance of Z DNA binding func-
tion for this interaction. Deletions which affect the transac-
tivation domain of Z also significantly decreased the com-
bined effect of Z and c-myb, although in each case the
combined effect was still slightly greater than the additive
effect of each transactivator alone (Fig. 9A). These results
suggest that both the transactivation domain and the DNA
binding domain of Z are important for cooperation with
c-myb.
The DNA binding domain of c-Myb is also important for
synergy with Z. The DNA binding domain of c-Myb has been
previously localized to the amino-terminal portion of the
protein (14, 22, 28). The c-myb DNA binding domain is
contained within a set of three imperfect 51- to 52-amino-
acid repeats (22, 28). Although the first repeat does not
appear to be essential for binding to the consensus c-myb
response element, the second and third repeats do appear to
be required for binding (22). Previous investigators have
shown that transactivation of the heat shock promoter by
c-myb, which does not appear to involve a DNA binding
mechanism, is still efficient even when the first and second
repeats are deleted together (27). In contrast, transactivation
of promoters linked to the consensus c-myb response ele-
ment, which does require c-Myb binding, is negligible if the
first and second repeats together are deleted (27).
We constructed a deletion of c-Myb that specifically
removed the first and second 51- to 52-amino-acid repeats
and tested this construct for the ability to transactivate the
BMRF1 promoter in conjunction with Z. Previous investi-
gators have shown that deletion of the first and second
repeats does not reduce protein stability or impair nuclear
localization of the c-myb protein (22, 27) (although there is
some evidence that the equivalent region may be required
for v-myb nuclear localization in avian erythroid cells [23]).
As shown in Fig. 9C, removal of the first and second repeats
from the amino-terminal end of the c-myb protein essentially
abolished the ability of c-myb to interact synergistically with
Z. This finding suggests that the DNA binding function of
c-Myb is required for the observed Zic-myb interaction.
However, since we have not yet confirmed that this mutant
stably localizes to the nucleus in Jurkat cells, we cannot
totally exclude the possibility that the lack of synergy with
this mutant is secondary to the inability of this mutant to
localize in the nucleus.
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DISCUSSION
The EBV transactivating protein Z plays a key role in the
disruption of viral latency. The Z protein binds to AP-1 sites
as a homodimer and (despite its sequence similarity with
c-Fos) is not capable of heterodimerizing with either c-Fos
or c-Jun (4). However, our data (21) demonstrate tissue
specificity in the ability of certain promoters to respond to Z,
suggesting that Z transactivation of these promoters is likely
to involve additional cellular transcription factors. In this
paper, we report the first evidence that a cellular factor,
c-myb, can interact synergistically with the Z transactivator
in lymphoid cells.
There are several lines of evidence to suggest that tran-
scriptional activation by the c-myb or v-myb protein may
involve interactions with other cellular transcription factors.
First, in a recent report by Ibanez and Lipsick (24), the
authors found that binding of the viral myb protein to
consensus Myb binding sites was required but not sufficient
for activation of linked reporter genes and concluded that
transactivation by v-myb may require interaction with an-
other DNA-bound transcription factor. Second, the Myb-
related BAS1 protein in Saccharomyces cerevisiae activates
the HIS4 gene only in cooperation with a second transcrip-
tion factor, BAS2 (a homeodomain protein) (53). Third, the
transforming effects of v-myb are highly tissue specific,
suggesting that interactions with tissue-specific factors are
likely to be required for the transcriptional effects of the myb
proteins. Fourth, at least one promoter (the heat shock
promoter) can be activated by v-myb through a mechanism
that does not appear to involve direct DNA binding (27) and
therefore is likely to be mediated through interaction with
cellular transcription factors.
At this point, the exact mechanism by which the Z and
c-myb proteins can synergistically interact to stimulate
BMRF1 and SV40 promoters in lymphoid cells, but not
epithelial cells, is not determined. Although our data do not
totally exclude the possibility that this effect is due to the
ability of Z to enhance c-myb-induced transactivation, it
seems much more likely that for the BMRF1 promoter, at
least, it is c-myb which enhances Z-induced transactivation.
Z binding to the BMRF1 promoter appears to be a crucial
element in this interaction, since (i) destruction of the AP-1
site by either 5' deletion or site-directed mutation of the
BMRF1 promoter significantly decreases the combined ef-
fect of the Zlc-myb combination on BMRF1 promoter activ-
ity, (ii) simultaneous destruction of both Z binding sites (the
AP-1 site and the upstream ZRE) totally abolishes the
Zlc-myb effect, and (iii) a site-directed mutation in the Z
protein which impairs DNA binding but does not affect
protein stability or nuclear localization also abolishes the
ability of Z to interact synergistically with c-myb.
The mechanism by which c-myb contributes to Z-induced
transactivation of the BMRF1 and SV40 promoters is not yet
clear. Our data suggest that direct c-Myb binding to the
BMRF1 promoter is unlikely, given that we were unable to
demonstrate binding in vitro, and mutation of the most likely
potential c-Myb binding in the promoter did not diminish the
combined effect of Z and c-myb. However, deletion of the
DNA binding domain in the c-myb protein did abolish the
ability of c-myb to interact synergistically with Z. This
requirement for the c-Myb DNA binding domain could
reflect an indirect mechanism involving activation by c-myb
of another cellular transcription factor, rather than direct
c-Myb binding to the BMRF1 promoter. Alternatively, the
amino-terminal domain of c-Myb may encode other func-
tions in addition to DNA binding. The latter possibility is
suggested in a recent report by Lane et al. (32), who found
that a linker insertion mutation within the DNA binding
domain of v-Myb, which did not affect DNA binding capac-
ity or nuclear localization, nevertheless inhibited transacti-
vation and transformation by v-myb. Given that we have not
yet confirmed that our particular mutant localizes to the
nucleus in Jurkat cells, it is still a possibility that inability of
this mutant c-myb protein to enter the nucleus explains our
results.
Interestingly, the SV40 early promoter has been previ-
ously found to contain a number of functional Myb binding
sites (40). One of the weakest binding sites in SV40, desig-
nated MBS II, is present within the pAlOCAT construct
used in these experiments, and like the potential Myb
binding site in the BMRF1 promoter, the MBS II site
overlaps an AP-1 site (33). This finding suggests that the
ZIc-myb effect on the SV40 promoter may indeed be medi-
ated by a mechanism involving binding of both proteins to
this promoter, and that perhaps we were unable to detect
v-Myb binding to the BMRF1 promoter because binding to
this site is weaker than binding to the consensus site. It is
possible that c-Myb binding to sites which are relatively
weak in vitro (such as the MBS II site) is stabilized by
interactions with cellular factors in vivo. However, the MBS
II site, when multimerized and linked to a heterologous
promoter, was found to confer negative regulation in the
presence of c-myb in CV1 cells (40). Therefore, the effect of
a particular Myb binding site on promoter activity may well
depend on the cell type tested, the relative proportions of the
different members of the Myb family of proteins (A-Myb
versus B-Myb versus c-Myb), and the presence or absence
of nearby binding sites for other transcription factors.
Our data suggest the possibility that protein-protein inter-
actions occur between c-myb and Z. Recent reports from
several laboratories have demonstrated protein-protein in-
teractions between AP-1 and the glucocorticoid receptor (9,
60), and these interactions do not necessarily require binding
sites for both proteins. In addition, the papillomavirus E2
protein has been recently shown to directly interact with the
Spl transcription factor, and this interaction is observed if
either an E2 binding site or an Spl binding site is present
(34). These results offer a precedent for the interaction
observed here between Z and c-myb in which the c-myb
protein does not appear to bind to the relevant promoter.
Interestingly, the carboxy-terminal half of c-Myb, which has
been shown to function as a negative regulator of c-myb
transactivation (46), contains a putative leucine zipper motif
and could potentially interact with the Z protein through this
region. Alternatively, protein-protein interactions between
c-myb and Z might involve the DNA binding domain of
c-Myb, which was found in this study to be required for
synergy with Z. At this point, however, we have no evidence
that direct protein-protein interactions between Z and c-myb
occur. Specifically, we have not found that the combination
of Z and c-myb affects Z or c-myb protein binding to the
BMRF1 promoter in vitro (25a).
Regardless of the precise mechanism, our demonstration
that the c-myb protein can interact synergistically with Z to
activate not only the EBV BMRF1 promoter but also the
SV40 early promoter suggests that c-myb is likely to have
similar synergistic interactions with cellular transcription
factors. Whether the synergistic interaction demonstrated
here between Z and c-myb is important in EBV infection
remains to be determined. We have preliminary data that
several other EBV early promoters are transactivated more
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efficiently in lymphoid cells by the combination of Z and
c-myb than by Z alone (25a). It is known that c-myb
expression in pre-B cells is much higher than in mature B
cells (1). Interestingly, EBV infection of precursor B-cell
lines has been shown to be unusually productive in compar-
ison with infection of mature B-cell lines (18), suggesting that
the high constitutive expression of c-myb in precursor B
cells might facilitate productive viral infection.
The ability of Z alone to function efficiently in HeLa cells
but not Jurkat cells is somewhat paradoxical, since the level
of endogenous c-myb would be expected to be higher in
Jurkat cells (38). However, it is quite possible that the level
of total myb activity (including A-myb and B-myb) is higher
in HeLa cells, accounting for the increased efficiency of Z in
this cell type. The B-myb gene product, which is present in
a wide variety of cells (42), is now known to bind to c-Myb
binding sites and function as a transcriptional transactivator
(39). We do not yet know whether B-myb, like c-myb, can
interact synergistically with the Z transactivator. Since
HeLa cells are known to contain papillomavirus, it is also
possible that a papillomavirus-encoded protein can substi-
tute for the c-Myb function. Alternatively, the inherent
differences in the transcriptional environment in Jurkat
versus HeLa cells may dictate a requirement for c-myb
helper function in the first cell type which is unnecessary in
the second.
There is some evidence that an EBV-encoded IE gene
product, BRLF1(R) (19, 20), may provide a functional sub-
stitute for c-myb in activation of the BMRF1 promoter. We
have previously shown that the R gene product, like c-Myb,
can interact synergistically with Z in activating the BMRF1
promoter in lymphoid cells but not epithelial cells (21). We
have also found that the R transactivator effect on c-myc
promoter regulation is similar to the previously described
effect of c-Myb (10, 19a). However, the functional similar-
ities between R and c-Myb are clearly limited, in that we
have been unable to show that the R transactivator activates
promoter constructs containing multiple copies of the con-
sensus myb response element or that c-Myb transactivates
promoter constructs containing known R-responsive targets
(5, 8, 25a, 26).
The data presented in this report emphasize that activation
of responsive promoters by Z is likely to involve not only the
requirement for Z binding to these promoters but also
complex interactions between the Z protein and cellular
transcription factors. It appears that the cooperative inter-
action of Z with other transcription factors (either the virally
encoded R transactivator or the cellularly encoded c-myb
transactivator) is required for maximal Z effect on the
BMRF1 promoter in lymphoid cells.
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